New Biginelli derivatives with trifluoro extension as inhibitors of epidermal growth factor receptor tyrosine kinase: molecular docking study in comparison with monastrol-Reference-Cited by-同舟云学术

New Biginelli derivatives with trifluoro extension as inhibitors of epidermal growth factor receptor tyrosine kinase: molecular docking study in comparison with monastrol

Published:2023-04-28 Issue:1 Volume:35 Page:191-208
ISSN:1040-0400
Container-title:Structural Chemistry
language:en
Short-container-title:Struct Chem

Author:

Wazalwar Sachin S.^ORCID,Perdih Franc^ORCID

Funder

Gondwana University, Gadchiroli

Slovenian Research Agency

Publisher

Springer Science and Business Media LLC

Subject

Physical and Theoretical Chemistry,Condensed Matter Physics

Link

https://link.springer.com/content/pdf/10.1007/s11224-023-02174-4.pdf

Reference44 articles.

1. Tayebee R, Amini MM, Ghadamgahi M, Armaghan M (2013) H5PW10V2O40/Pip-SBA-15: a novel reusable organic-inorganic hybrid material as potent Lewis acid catalyst for one-pot solvent-free synthesis of 3,4-dihydropyrimidinones. J Mol Catal A: Chem 366:266–274. https://doi.org/10.1016/j.molcata.2012.10.004

2. Razzaghi-Asl N, Kamrani-Moghadam M, Farhangi B, Vahabpour R, Zabihollahi R, Sepehri S (2019) Design, synthesis and evaluation of cytotoxic, antimicrobial, and anti-HIV-1 activities of new 1,2,3,4-tetrahydropyrimidine derivatives. Res Pharm Sci 14:155–166. https://doi.org/10.4103/1735-5362.253363

3. Matos LHS, Masson FT, Simeoni LA, Homem-deMello M (2018) Biological activity of dihydropyrimidinone (DHPM) derivatives: a systematic review. Eur J Med Chem 143:1779–1789. https://doi.org/10.1016/j.ejmech.2017.10.073

4. Jin T, Zhang S, Li T (2002) p-Toluenesulfonic acid catalyzed efficient synthesis of dihydropyrimidines: improved high yielding protocol for the Biginelli reaction. SyntCommuns 32:1847–1851. https://doi.org/10.1081/SCC-120004068

5. Marques LA, Semprebon SC, Niwa AM, D’Epiro GFR, Sartori D, de Fátima Â (2016) Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells. Naunyn-Schmiedebergs Arch Pharmacol 389:1279–1288. https://doi.org/10.1007/s00210-016-1292-1299